The quest for effective Ebola treatment: Ebola VP35 is an evidence-based target for dsRNA drugs

por Mitchell, William M, Carter, William A
Publicado 2014

Discordant Biological and Toxicological Species Responses to TLR3 Activation

por Mitchell, William M., Nicodemus, Christopher F., Carter, William A., Horvath, Joseph C., Strayer, David R.
Publicado 2014

Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administe...

por Strayer, David R., Carter, William A., Stouch, Bruce C., Stittelaar, Koert J., Thoolen, Robert J.M.M., Osterhaus, Albert D.M.E., Mitchell, William M.
Publicado 2014

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

por Strayer, David R., Carter, William A., Stouch, Bruce C., Stevens, Staci R., Bateman, Lucinda, Cimoch, Paul J., Lapp, Charles W., Peterson, Daniel L., Mitchell, William M.
Publicado 2012